Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma

Takuma Hayashi, Akiko Horiuchi, Kenji Sano, Nobuyoshi Hiraoka, Yae Kanai, Tanri Shiozawa, Susumu Tonegawa, Ikuo Konishi

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Uterine tumors are the most common type of gynecologic neoplasm. Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body. Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS. Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression. We found LMP2 expression is absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.

Original languageEnglish
Pages (from-to)711-717
Number of pages7
JournalProtein and Cell
Volume1
Issue number8
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Leiomyosarcoma
Proteasome Endopeptidase Complex
Tumors
Animals
Animal Models
Biomarkers
Gene therapy
Muscle
Leiomyoma
Hormones
Tissue
Neoplasms
Female Genital Neoplasms
LMP-2 protein
DNA
Cervix Uteri
Genetic Therapy

Keywords

  • diagnostic biomarker
  • LMP2
  • uterine leiomyoma
  • uterine leiomyosarcoma

ASJC Scopus subject areas

  • Biotechnology
  • Cell Biology
  • Drug Discovery
  • Biochemistry

Cite this

Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. / Hayashi, Takuma; Horiuchi, Akiko; Sano, Kenji; Hiraoka, Nobuyoshi; Kanai, Yae; Shiozawa, Tanri; Tonegawa, Susumu; Konishi, Ikuo.

In: Protein and Cell, Vol. 1, No. 8, 2010, p. 711-717.

Research output: Contribution to journalReview article

Hayashi, T, Horiuchi, A, Sano, K, Hiraoka, N, Kanai, Y, Shiozawa, T, Tonegawa, S & Konishi, I 2010, 'Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma', Protein and Cell, vol. 1, no. 8, pp. 711-717. https://doi.org/10.1007/s13238-010-0095-x
Hayashi, Takuma ; Horiuchi, Akiko ; Sano, Kenji ; Hiraoka, Nobuyoshi ; Kanai, Yae ; Shiozawa, Tanri ; Tonegawa, Susumu ; Konishi, Ikuo. / Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. In: Protein and Cell. 2010 ; Vol. 1, No. 8. pp. 711-717.
@article{2b56204399814912967871ff9f7e2a48,
title = "Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma",
abstract = "Uterine tumors are the most common type of gynecologic neoplasm. Uterine leiomyosarcoma (LMS) is rare, accounting for 2{\%} to 5{\%} of tumors of the uterine body. Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS. Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40{\%} by 14 months of age. It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression. We found LMP2 expression is absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.",
keywords = "diagnostic biomarker, LMP2, uterine leiomyoma, uterine leiomyosarcoma",
author = "Takuma Hayashi and Akiko Horiuchi and Kenji Sano and Nobuyoshi Hiraoka and Yae Kanai and Tanri Shiozawa and Susumu Tonegawa and Ikuo Konishi",
year = "2010",
doi = "10.1007/s13238-010-0095-x",
language = "English",
volume = "1",
pages = "711--717",
journal = "Protein and Cell",
issn = "1674-800X",
publisher = "Springer-Verlag GmbH and Co. KG",
number = "8",

}

TY - JOUR

T1 - Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma

AU - Hayashi, Takuma

AU - Horiuchi, Akiko

AU - Sano, Kenji

AU - Hiraoka, Nobuyoshi

AU - Kanai, Yae

AU - Shiozawa, Tanri

AU - Tonegawa, Susumu

AU - Konishi, Ikuo

PY - 2010

Y1 - 2010

N2 - Uterine tumors are the most common type of gynecologic neoplasm. Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body. Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS. Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression. We found LMP2 expression is absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.

AB - Uterine tumors are the most common type of gynecologic neoplasm. Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body. Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS. Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression. We found LMP2 expression is absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.

KW - diagnostic biomarker

KW - LMP2

KW - uterine leiomyoma

KW - uterine leiomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=79953158757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953158757&partnerID=8YFLogxK

U2 - 10.1007/s13238-010-0095-x

DO - 10.1007/s13238-010-0095-x

M3 - Review article

VL - 1

SP - 711

EP - 717

JO - Protein and Cell

JF - Protein and Cell

SN - 1674-800X

IS - 8

ER -